Showing results (191-200 of 324) with videos related to
Sort By:
Pageof 33
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 studyShirish M Gadgeel, James P Stevenson, Corey J Langer, et al.Lung Cancer (Amsterdam, Netherlands)|November 5, 2013
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopyTzu-Hsiu Tsai, Ching-Yao Yang, Chao-Chi Ho, et al.Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysisLi-Yang Chen, Miguel A Molina-Vila, Sheng-Yuan Ruan, et al.Investigational New Drugs|March 3, 2019
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumorsJih-Hsiang Lee, Tom Wei-Wu Chen, Chih-Hung Hsu, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 14, 2017
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBin-Chi Liao, Ya-Ying Bai, Jih-Hsiang Lee, et al.JTO Clinical and Research Reports|September 30, 2021
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLCBin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, et al.Journal of Biomedical Science|October 9, 2025
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLCChia-Chi Hsu, Derek De-Rui Huang, Wei-Hsun Hsu, et al.British Journal of Cancer|December 23, 2016
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6Yi-Long Wu, Lecia V Sequist, Cheng-Ping Hu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung CancerHelena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, et al.American Journal of Respiratory and Critical Care Medicine|November 2, 2010
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitorTzu-Hua Chang, Meng-Feng Tsai, Kang-Yi Su, et al.Pageof 33